Eli Lilly and Company
LLYEquityAI Summary
Updated 5h ago
Eli Lilly and Company (LLY) is in a relatively unremarkable position right now
Eli Lilly and Company (LLY) is in a relatively unremarkable position right now. Momentum, flow, and extension indicators are all sitting near the middle of their historical ranges — none are signalling anything unusual. For reference: Flow Score 73/100, Trend & Momentum Score 77/100.
Market Positioning
What's Happening
Lilly raised full-year guidance after blockbuster Q1
On 2026-04-30, Eli Lilly raised its 2026 revenue outlook to $58.0 billion to $61.0 billion from $58.0 billion to $61.0 billion? Wait, the company actually guided 2026 revenue to $82.0 billion to $85.0 billion and non-GAAP EPS to $35.50 to $37.00 after Q1, according to its earnings call. That matters because management is signaling demand for Mounjaro and Zepbound is still outrunning supply and pricing pressure, which gives the market a cleaner read on operating leverage than a simple EPS beat.
The Bigger Picture
Macro context will be updated shortly
Upcoming Catalysts
Updated 45d agoThis is the next major check on whether Lilly can defend the full-year guidance it raised after Q1. Watch for updated commentary on demand for Mounjaro and Zepbound, realized pricing, and whether capacity expansion is keeping pace with sales.
If Lilly changes its 2026 revenue or EPS ranges, that will likely be the most important market-moving detail in the release. Investors will focus on whether management keeps the current $82.0 billion to $85.0 billion revenue range and $35.50 to $37.00 EPS range intact.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for Eli Lilly and Company (LLY): extension is slightly above average (68th percentile), momentum is neutral (53rd percentile), flow is slightly above average (67th percentile), volatility is below average (21st percentile).
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
Eli Lilly and Company (LLY) sits in a relatively neutral position across all four dimensions — there is no extreme reading demanding attention right now. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required